Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002–2004
- 16 December 2005
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 53 (4) , 265-271
- https://doi.org/10.1016/j.diagmicrobio.2005.10.002
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin BEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Antibiotic policies in Central Eastern EuropeInternational Journal of Antimicrobial Agents, 2004
- Epidemiology and control of antibiotic resistance in the intensive care unitCurrent Opinion in Infectious Diseases, 2004
- Antibiotic resistance – from pathogen to disease surveillanceClinical Microbiology & Infection, 2002
- The increasing role of Acinetobacter species as nosocomial pathogensCurrent Infectious Disease Reports, 2001
- Emerging Importance of Multidrug‐ResistantAcinetobacterSpecies andStenotrophomonas maltophiliaas Pathogens in Seriously Ill Patients: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997–1999)Clinical Infectious Diseases, 2001
- Antimicrobial Resistance in European Isolates of Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in TurkeyJournal of Antimicrobial Chemotherapy, 2000
- Meropenem: clinical response in relation to in vitro susceptibilityClinical Microbiology & Infection, 2000
- Current Guidelines for the Treatment and Prevention of Nosocomial InfectionsDrugs, 1999